What Are the U.S. Market Access Levers and Hurdles Facing Orally Administered, Small-Molecule Targeted Oncology Drugs for Renal Cell Carcinoma and Hepatocellular Carcinoma? | Physician & Payer Forum | US| 2015

launch Related Market Assessment Reports

• Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast

  April 2024

  The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…

• Psoriasis – Geographic Focus: China – Psoriasis – China In-Depth (China)

  Non-TNF biologics (e.g., IL-17 inhibitors) are gaining momentum in China in the treatment of psoriasis, particularly moderate to severe disease. We expect that the growing psoriasis armamentarium…

• Idiopathic Pulmonary Fibrosis – Unmet Need – Detailed, Expanded Analysis (US/EU)

  April 2024

  Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. IPF…

• Ulcerative Colitis – Unmet Need – Detailed, Expanded Analysis: Moderate to Severe Ulcerative Colitis (US/EU)

  TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s…

• Obesity/Overweight – Geographic Focus: China – Obesity / Overweight – China In-Depth (China)

  April 2024

  Obesity is recognized as a chronic disease and public health concern globally. The primary goals of obesity treatment are to improve patients’ health outcomes and quality of life. Physicians…